INmune Bio submits Phase 2 MINDFuL manuscript; highlights subgroup benefit and no ARIA

Inmune Bio, Inc.

Phase 2 MINDFuL trial of XPro1595 missed primary endpoint overall but showed positive trends in ADi subgroup with high inflammatory burden.
No amyloid-related imaging abnormalities (ARIA) observed, even in high-risk patients (APOE4 carriers, anticoagulants, microbleeds).
Manuscript submitted to npj Dementia (Nature Portfolio); preprint available on medRxiv.
Expects FDA feedback for end-of-Phase 2 discussions in Q1 2026.
XPro1595 selectively neutralizes soluble TNF, targeting neuroinflammation in precision medicine approach.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.